The Official Website of the Acid Maltase Deficiency Association

It is difficult to say what is impossible for the dreams of yesterday are the hopes of today and the reality of tomorrow. - Robert H. Goddard

Editorials

IPA Statement Regarding The Management Of Myozyme Supply - Adivce To Pompe Patients

By: IPA posted on: January 14, 2009

Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSD Therapeutics to insist that an adequate inventory of the product was kept to ensure continuous supply to all patients receiving the treatment; whether through their commercial or compassionate-use programs. Regretfully, in July 2008 Genzyme released a notification that supply would be tight in 2009 until a larger-scale production facility in Belgium is approved by the European Medicines Agency (EMEA).

Disclaimer: The AMDA does not endorse any of the products, medications, treatments or information reported herein. The website and its contents is intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.

Address: AMDA PO Box 700248
San Antonio, Texas 78270 USA